Medication Guide - 8/21/2026

 

Medication guides are FDA- approved documents that address issues that are specific to particular drugs, and can help patients avoid serious adverse events (side effects). This database does not include Medication Guides for FDA-approved allergenic or cellular/tissue products (see  FDA Online Label Repository  or DailyMed  for these Medication Guides).  More

Drug Name Active Ingredient Form;Route Appl. No. Company Date
Actoplus MET Metformin Hydrochloride; Pioglitazone Hydrochloride TABLET;ORAL 021842 TAKEDA PHARMS USA 08/18/2026
Invokamet Canagliflozin; METformin Hydrochloride TABLET;ORAL 204353 JANSSEN PHARMS 08/18/2026
Invokamet XR Canagliflozin; METformin Hydrochloride TABLET, EXTENDED RELEASE;ORAL 205879 JANSSEN PHARMS 08/18/2026
Janumet Metformin Hydrochloride; Sitagliptin Phosphate TABLET;ORAL 022044 MERCK SHARP DOHME 08/18/2026
Jentadueto Linagliptin; METformin Hydrochloride TABLET;ORAL 201281 BOEHRINGER INGELHEIM 08/18/2026
Jentadueto XR Linagliptin; METformin Hydrochloride TABLET, EXTENDED RELEASE;ORAL 208026 BOEHRINGER INGELHEIM 08/18/2026
Kombiglyze XR Metformin Hydrochloride; Saxagliptin Hydrochloride TABLET, EXTENDED RELEASE;ORAL 200678 ASTRAZENECA AB 08/18/2026
Opdivo Nivolumab INJECTABLE;INJECTION 125554 BRISTOL MYERS SQUIBB 08/18/2026
Segluromet Ertugliflozin; METformin Hydrochloride TABLET;ORAL 209806 MERCK SHARP DOHME 08/18/2026
Synjardy Empagliflozin; METformin Hydrochloride TABLET;ORAL 206111 BOEHRINGER INGELHEIM 08/18/2026
Synjardy XR Empagliflozin; METformin Hydrochloride TABLET, EXTENDED RELEASE;ORAL 208658 BOEHRINGER INGELHEIM 08/18/2026
Trijardy XR Empagliflozin; Linagliptin; METformin Hydrochloride TABLET, EXTENDED RELEASE;ORAL 212614 BOEHRINGER INGELHEIM 08/18/2026
Xigduo XR Dapagliflozin; METformin Hydrochloride TABLET, EXTENDED RELEASE;ORAL 205649 ASTRAZENECA AB 08/18/2026
Yesintek Ustekinumab-Kfce INJECTABLE;SUBCUTANEOUS 761406 BIOCON BIOLOGICS INC 08/18/2026
Zituvimet Sitagliptin, METformin Hydrochloride TABLET;ORAL 216743 ZYDUS PHARMACEUTICALS 08/18/2026
This email was sent to Esdek@podam.pl using Granicus Communications Cloud on behalf of: U.S. Food and Drug Administration · 
10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA		 GovDelivery logo